Loading
Life sciences · Phase 3 Trial
ClinicalTrials.gov · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04665856). This is a study registration, not published results. Lead sponsor: Hoffmann-La Roche. Recruitment status: COMPLETED. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 123 participants (ACTUAL). Conditions: Small Cell Lung Carcinoma. Interventions: DRUG: Tiragolumab; DRUG: Atezolizumab; DRUG: Carboplatin; DRUG: Etoposide; DRUG: Tiragolumab Matching Placebo. Primary outcome measures: Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS) , From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 32.3 months); Overall Survival (OS) in the PAS , From randomization to death from any cause (up to approximately 32.3 months). Brief summary: The purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.